Salarius Pharmaceuticals, Inc. (SLRX) Q4 2021 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good day and thank you for standing by. Welcome to Q4 2021 Solaris Pharmaceuticals earnings webcast and conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to Jason Randall of Cibaran Strategic Advisors. Please go ahead. Good afternoon, and thank you for joining Solaris Pharmaceuticals' 2021 Fourth Quarter and Full Year Financial and Corporate Results Call. This afternoon, Solaris Pharmaceuticals issued a press release detailing its financial results for the three months and full year ended December 31, 2021, which we encourage listeners to read. The press release can be found in the news section of SolarisPharma.com. Before beginning today's call, I would like to make the following statement. Today, we'll be making certain forward-looking statements about operating metrics, future expectations, plans, events, and circumstances, including statements about our strategy, future operations, the development and effectiveness of our investigational drug candidates, SecloDemsat, and SP3164. as well as our targeted protein degradation program, and expectations regarding our capital allocation and cash resources. These statements are based on our current expectations, and you should not place undue reliance on these statements. Action results may differ materially due to our risks and uncertainties, including those detailed in the risk factors section of Solaris Pharmaceutical's annual report on Form 10-K for the year ended 2021, and subsequent quarterly reports on Form 10-Q which have be...